Analisa DiFeo

ORCID: 0000-0001-8319-6763 · 5 papers in corpus
lab-animal 2026
Cancer research ·doi:10.1158/0008-5472.can-25-1527

UNLABELLED: Mitigating DNA damage in the fallopian tube epithelium (FTE) is essential for preventing tubo-ovarian high-grade serous carcinoma (HGSC). In this study, we demonstrated that the stimulator of interferon genes (STING) is abundant…

2026
·doi:10.1158/0008-5472.32675390

Quantification of IHC staining for STING conducted on a tumor microarray including cores from healthy FT, FT from patients with gynecological inflammation resulting from endometriosis or chronic salpingitis, and Stage I/Stage II HGSC

other 2021
The journal of pathology. Clinical research ·doi:10.1002/cjp2.230

Ovarian carcinoma histotypes are distinct diseases with variable clinical outcomes and response to treatment. There is a need for new subtype-specific treatment modalities, especially for women with widespread and chemo-resistant disease. S…

lab-animal 2019
Cancer research ·doi:10.1158/0008-5472.can-19-0215

Chemoresistance is driven by unique regulatory networks in the genome that are distinct from those necessary for cancer development. Here, we investigate the contribution of enhancer elements to cisplatin resistance in ovarian cancers. Epig…

lab-animal 2015
Oncotarget ·doi:10.18632/oncotarget.4690

Resistance to platinum-based chemotherapy is the major barrier to treating epithelial ovarian cancer. To improve patient outcomes, it is critical to identify the underlying mechanisms that promote platinum resistance. Emerging evidence supp…